S. E. Belov
Research Subjects
S. E. Belov has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Аleksey N. Boyko
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
3 shared publications - E. A. Dubchenko
Veresaev City Clinical Hospital
2 shared publications - Mikhail Borisovich Dolgushin
Federal Center of Brain Research and Neurotechnologies
2 shared publications - A. A. Kuznetsov
Federal Center for Brain and Neurotechnologies, FMBA of Russia
1 shared publication - A. D. Kukushkina
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia
1 shared publication - A. I. Tatarenko
Buyanov Moscow Clinical Hospital
1 shared publication
Latest Publications
- Open Access
- 8 August 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 120-127
Cladribine in tablets in real clinical practice: Results of treatment of 267 patients with multiple sclerosis in Moscow
Introduction. Over the past 30 years, there has been a dramatic change in approaches to the treatment of multiple sclerosis (MS), due to the development of a large number of drugs with different mechanisms of action for the disease-modifying treatment (DMT) of MS.Aim. To form, based on the analysis of the obtained data, an optimal algorithm for the management of patients with MS receiving cladribine tablets in the conditions of real clinical practice.Materials and methods. A retrospective analysis of the data obtained on the background of therapy with cladribine in MS patients at the end of 2024 was conducted on the basis of the Moscow inter-district departments of MS. The data from outpatient records of MS patients treated with cladribine from 2021 to 2023 were used as research material. Data collection was carried out on the initial clinical and demographic characteristics of patients, as well as indicators of the effectiveness of therapy (average annual frequency of exacerbations, activity according to MRI data and progression according to the EDSS scale) and the presence of adverse reactions against the background of therapy with cladribine.Results. This publication presents the experience of using the drug cladribine in real clinical practice in 267 MS patients in Moscow in the period from 2021 to 2023. Patients who underwent two full annual courses of therapy showed a significant reduction in the mean annual frequency of exacerbations and brain MRI activity after the first year of therapy. There was also no significant increase in neurological deficits according to the EDSS scale. During the safety analysis, good tolerability of the drug was noted. The spectrum of adverse events and their frequency were comparable to the data of the instructions for medical use. Conclusion. Effective treatment of MS patients requires optimizing therapy, balancing benefits and risks, and long-term treatment planning from the moment of diagnosis. All these principles can be met with an understanding of the mechanism of action of the drugs and clear adherence to recommendations for monitoring the duration of washout periods when switching from one MS-modifying drug to another.
- 8 August 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 120-127
Open AccessCladribine in tablets in real clinical practice: Results of treatment of 267 patients with multiple sclerosis in Moscow
Introduction. Over the past 30 years, there has been a dramatic change in approaches to the treatment of multiple sclerosis (MS), due to the development of a large number of drugs with different mechanisms of action for the disease-modifying treatment (DMT) of MS.Aim. To form, based on the analysis of the obtained data, an optimal algorithm for the management of patients with MS receiving cladribine tablets in the conditions of real clinical practice.Materials and methods. A retrospective analysis of the data obtained on the background of therapy with cladribine in MS patients at the end of 2024 was conducted on the basis of the Moscow inter-district departments of MS. The data from outpatient records of MS patients treated with cladribine from 2021 to 2023 were used as research material. Data collection was carried out on the initial clinical and demographic characteristics of patients, as well as indicators of the effectiveness of therapy (average annual frequency of exacerbations, activity according to MRI data and progression according to the EDSS scale) and the presence of adverse reactions against the background of therapy with cladribine.Results. This publication presents the experience of using the drug cladribine in real clinical practice in 267 MS patients in Moscow in the period from 2021 to 2023. Patients who underwent two full annual courses of therapy showed a significant reduction in the mean annual frequency of exacerbations and brain MRI activity after the first year of therapy. There was also no significant increase in neurological deficits according to the EDSS scale. During the safety analysis, good tolerability of the drug was noted. The spectrum of adverse events and their frequency were comparable to the data of the instructions for medical use. Conclusion. Effective treatment of MS patients requires optimizing therapy, balancing benefits and risks, and long-term treatment planning from the moment of diagnosis. All these principles can be met with an understanding of the mechanism of action of the drugs and clear adherence to recommendations for monitoring the duration of washout periods when switching from one MS-modifying drug to another.
- 8 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (7) , 28-33
Results of a 5-year project for the early diagnosis of multiple sclerosis in first-line blood relatives (RADIRS program)
Objective. A nationwide examination of blood relatives of MS patients using free brain MRI for possible detection of RIS and subsequent early diagnosis of MS. Material and methods. In more than 60 regions of the country, relatives of the first degree of kinship (children and siblings) aged 18—50 years of patients with an undisputed diagnosis of MS according to the McDonald criteria in 2017 who were receiving DMTs were called for a free MRI scan of the brain. When focal changes were detected, additional analysis was performed to exclude non-specific vascular changes, migraines, and follow-up was performed for everyone. If RIS was suspected, participants were necessarily referred for inpatient examination to the neurological department No. 2 Federal Medical Center for Brain and Neurotechnology or other large MS centers (by territorial affiliation) for repeated MRI of the brain and spinal cord with contrast, clinical assessment and determination of oligoclonal IgG in cerebrospinal fluid (type of synthesis). Results. For 3 years, information was collected on the results of 416 MRI examinations of healthy first-degree relatives (children and siblings) aged 18—50 years. MRI results. The majority of healthy relatives of the patients (74.6%) showed no focal changes in brain tissue. In 56 examined patients (14.5%), nonspecific or vascular changes were detected that did not imply a demyelinating process. However, 48 people (11.5%) had changes that required additional examination. Only half of them reached the Federal Medical Center and other large centers (the entire survey was proposed to be conducted only within the framework of compulsory medical insurance). Of the 24 patients, 14 were diagnosed with MS and recommended to start treatment urgently. Among the risk factors, it should be noted the transmission of the disease from the mother, the presence of OCI in the CSF, the presence of hypointernative foci on T1-VI, even without accumulation of contrast, as well as the detection of foci in the spinal cord. Conclusion. It is necessary to strengthen monitoring of family members of MS patients in order to take timely measures in case of transition from RIS to MS, without starting the course of infection.
- 8 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (7) , 28-33
Results of a 5-year project for the early diagnosis of multiple sclerosis in first-line blood relatives (RADIRS program)
Objective. A nationwide examination of blood relatives of MS patients using free brain MRI for possible detection of RIS and subsequent early diagnosis of MS. Material and methods. In more than 60 regions of the country, relatives of the first degree of kinship (children and siblings) aged 18—50 years of patients with an undisputed diagnosis of MS according to the McDonald criteria in 2017 who were receiving DMTs were called for a free MRI scan of the brain. When focal changes were detected, additional analysis was performed to exclude non-specific vascular changes, migraines, and follow-up was performed for everyone. If RIS was suspected, participants were necessarily referred for inpatient examination to the neurological department No. 2 Federal Medical Center for Brain and Neurotechnology or other large MS centers (by territorial affiliation) for repeated MRI of the brain and spinal cord with contrast, clinical assessment and determination of oligoclonal IgG in cerebrospinal fluid (type of synthesis). Results. For 3 years, information was collected on the results of 416 MRI examinations of healthy first-degree relatives (children and siblings) aged 18—50 years. MRI results. The majority of healthy relatives of the patients (74.6%) showed no focal changes in brain tissue. In 56 examined patients (14.5%), nonspecific or vascular changes were detected that did not imply a demyelinating process. However, 48 people (11.5%) had changes that required additional examination. Only half of them reached the Federal Medical Center and other large centers (the entire survey was proposed to be conducted only within the framework of compulsory medical insurance). Of the 24 patients, 14 were diagnosed with MS and recommended to start treatment urgently. Among the risk factors, it should be noted the transmission of the disease from the mother, the presence of OCI in the CSF, the presence of hypointernative foci on T1-VI, even without accumulation of contrast, as well as the detection of foci in the spinal cord. Conclusion. It is necessary to strengthen monitoring of family members of MS patients in order to take timely measures in case of transition from RIS to MS, without starting the course of infection.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (7) , 58-65
The central vein sign in the differential diagnosis of multiple sclerosis
Objective. To carry out a clinical and radiological assessment of the central vein sign (CVS) as a diagnostic marker for multiple sclerosis (MS) and other demyelinating and non-demyelinating diseases with focal brain damage, using clinical and laboratory examination data, as well as MRI. Material and methods. The results of clinical and neuroradiological examination of 107 patients diagnosed with MS or with other diseases accompanied by focal brain damage according to MRI data were analyzed. Results. CVS is a sensitive but low-specific diagnostic marker of MS. According to our data, the sensitivity and specificity of 40 and 50% of the threshold of perivenular lesions in the diagnosis of MS are the same and amount to 100% and 39.4%, respectively. Neither the type of MS course, nor the severity of the course, nor the intake of DMT (disease modifying treatment), affect the proportion of foci with CVS. The spread of the proportion of foci with CVS in patients with MS was 60—100%. The proportion of foci with CVS is below 40 and 50% of the threshold in patients with demyelinating and non-demyelinating diseases (NMOSD, migraine, systemic lupus erythematosus, Susak disease, CLIPPERS), which allows for differential diagnosis with MS. The proportion of foci with CVS comparable to MS in patients with acute disseminated encephalomyelitis, small vessel disease, as well as in patients with radiologically isolated syndrome does not allow using this symptom in the differential diagnosis of these conditions. Conclusion. The use of CVS as a diagnostic marker of MS is possible only in combination with the already existing diagnostic criteria of MS.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (7) , 58-65
The central vein sign in the differential diagnosis of multiple sclerosis
Objective. To carry out a clinical and radiological assessment of the central vein sign (CVS) as a diagnostic marker for multiple sclerosis (MS) and other demyelinating and non-demyelinating diseases with focal brain damage, using clinical and laboratory examination data, as well as MRI. Material and methods. The results of clinical and neuroradiological examination of 107 patients diagnosed with MS or with other diseases accompanied by focal brain damage according to MRI data were analyzed. Results. CVS is a sensitive but low-specific diagnostic marker of MS. According to our data, the sensitivity and specificity of 40 and 50% of the threshold of perivenular lesions in the diagnosis of MS are the same and amount to 100% and 39.4%, respectively. Neither the type of MS course, nor the severity of the course, nor the intake of DMT (disease modifying treatment), affect the proportion of foci with CVS. The spread of the proportion of foci with CVS in patients with MS was 60—100%. The proportion of foci with CVS is below 40 and 50% of the threshold in patients with demyelinating and non-demyelinating diseases (NMOSD, migraine, systemic lupus erythematosus, Susak disease, CLIPPERS), which allows for differential diagnosis with MS. The proportion of foci with CVS comparable to MS in patients with acute disseminated encephalomyelitis, small vessel disease, as well as in patients with radiologically isolated syndrome does not allow using this symptom in the differential diagnosis of these conditions. Conclusion. The use of CVS as a diagnostic marker of MS is possible only in combination with the already existing diagnostic criteria of MS.
- Open Access
- 15 August 2023
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (4) , 94–99
Paramagnetic rim sign in multiple sclerosis
To date, there is no accepted highly specific pattern for the detection of multiple sclerosis. Correct diagnosis is particularly difficult in situations where an atypical clinical picture of the disease is observed or nonstandard neuroimaging patterns are detected. Therefore, the scientific community has high hopes for the discovery of new markers that will allow clarification of the diagnosis in controversial cases. Currently, there is a lot of research focused on the study of an additional diagnostic MRI pattern – a sign of a paramagnetic rim. This symptom is associated with chronic smoldering central nervous system (CNS) lesions, is more commonly seen in young males, is found primarily in the periventricular region, and is also a promising predictor of disability and cognitive impairment. There is evidence that it is present in earlier stages of disease in “fresh” lesions of the CNS. However, further studies are needed to use this diagnostic MRI pattern in clinical practice.
- 15 August 2023
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (4) , 94–99
Open AccessParamagnetic rim sign in multiple sclerosis
To date, there is no accepted highly specific pattern for the detection of multiple sclerosis. Correct diagnosis is particularly difficult in situations where an atypical clinical picture of the disease is observed or nonstandard neuroimaging patterns are detected. Therefore, the scientific community has high hopes for the discovery of new markers that will allow clarification of the diagnosis in controversial cases. Currently, there is a lot of research focused on the study of an additional diagnostic MRI pattern – a sign of a paramagnetic rim. This symptom is associated with chronic smoldering central nervous system (CNS) lesions, is more commonly seen in young males, is found primarily in the periventricular region, and is also a promising predictor of disability and cognitive impairment. There is evidence that it is present in earlier stages of disease in “fresh” lesions of the CNS. However, further studies are needed to use this diagnostic MRI pattern in clinical practice.